Semaglutide vs Tirzepatide: What Actually Differs

One molecular difference drives the rest of the comparison

Semaglutide is a GLP-1 receptor agonist. It imitates glucagon-like peptide-1, a hormone your gut releases after you eat. That slows how fast the stomach empties, prompts insulin release when blood sugar is high, and reduces appetite signaling in the brain.

Tirzepatide does that and one more thing. It also activates the GIP receptor, for glucose-dependent insulinotropic polypeptide, a second incretin hormone. That is why it is usually described as a dual agonist rather than a GLP-1 drug. Everything else people argue about — average results, side effect texture, which brand name their prescriber writes — sits downstream of that single structural difference.

Two receptors instead of one is not automatically better for a given person. What it means is that these are different compounds with different labels, different approved uses, and different manufacturers. They also sit in different supply and coverage situations. Compare them as separate medications, not as two grades of one product.

Same molecule, different brand, different approved use

Semaglutide and tirzepatide are generic ingredient names. Each is sold under more than one brand name, and the brands are not interchangeable on paper even when the ingredient is identical. This is the part that confuses most people arriving from a search result, and it matters more than the mechanism for anything practical.

Semaglutide is marketed as Ozempic and as Wegovy as an injection, and as an oral tablet sold under both the Rybelsus and Ozempic names. Tirzepatide is marketed as Mounjaro and as Zepbound. Within each pair, one brand is approved for type 2 diabetes and the other for chronic weight management, with the approved population and the label wording differing accordingly.

That distinction is not marketing trivia. The approval your prescription is written under is what a pharmacy benefit reads, what a prior authorization form asks about, and what determines which manufacturer support program you can even apply to. Two people taking chemically identical drugs can face completely different paperwork, because one prescription was written under a diabetes indication and the other under a weight-management one.

What the evidence settles, and what it does not

Trial evidence to date has generally reported greater average weight loss with tirzepatide than with semaglutide in adults treated for obesity, including in direct comparison. That is the honest summary of the direction of the findings. No effect sizes appear here, because a number quoted secondhand and left to age is worse than no number.

What an average conceals is the more useful point. The response distributions for both drugs are wide, and they overlap heavily. Some people respond strongly to semaglutide and modestly to tirzepatide, and some the reverse. Nothing available today predicts which you are before you try. A population average is a statement about a trial cohort, not a forecast for one person.

There is also no good evidence that a drug which works better on average is the better drug for someone who cannot tolerate it, cannot reliably obtain it, or cannot get it covered. Adherence over months is what produces a result, and the practical constraints below are usually what determines adherence.

Side effects are similar in kind, not identical

Both drugs are dominated by gastrointestinal effects. The labels list nausea, diarrhea, vomiting, and constipation among the most frequently reported adverse reactions, along with abdominal pain, reduced appetite, and injection site reactions. Tirzepatide labeling also lists eructation — burping — which people switching between the two often notice as a difference.

Both carry a boxed warning based on rodent studies showing thyroid C-cell tumors. Both are labeled as contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Both labels also address pancreatitis, gallbladder disease, kidney injury related to dehydration from vomiting or diarrhea, and low blood sugar risk when the drug is combined with insulin or a sulfonylurea.

So switching from one to the other because of side effects is not an escape from the class. It is a conversation with a prescriber about a different molecule with a similar risk profile. Some people genuinely tolerate one better than the other. That is a real phenomenon, and not something to assume in advance.

Delivery and routine differ in ways people underrate

The injectable forms of both are once-weekly subcutaneous injections, which is a meaningful convenience compared with daily therapy. Semaglutide additionally exists in an oral tablet form. That changes the daily routine substantially, and it comes with its own administration requirements.

Device design differs too. Brand pens are supplied with a manufacturer's Instructions for Use and deliver fixed, labeled increments. Compounded preparations of either ingredient are typically supplied as a vial and syringe, where the person injecting is measuring a volume. That is one of the most consequential differences between what a person actually holds, and the compounded versus brand article covers it separately.

What usually decides it in practice

For most people the choice is not made by ranking the two drugs. It is made by what a prescriber judges appropriate for their history, what their pharmacy benefit will process, and what is actually in stock. Then by what they can tolerate at each step, and what they can sustain paying for over a long period.

Use a comparison like this one to arrive at a prescriber appointment holding three facts. These are two distinct drugs with distinct approvals. Both have brand names attached to different indications. The head-to-head averages are real but do not predict an individual. Those three are enough to ask better questions, which is the only thing an article can honestly do here.